Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Synonyms
2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure
2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure
Gemfibrozilum
Gemfibrozil
2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
Gemfibrozilo
Brand Names
Apo-gemfibrozil Cap 300mg USP
Riva-gemfibrozil
Gemfibrozil Tab 600mg
Dom-gemfibrozil
Gemfibrozil
PMS-gemfibrozil
Gemfibrozil Cap 300mg
Lopid 600mg
Nu-gemfibrozil Tab 600mg
Lopid Cap 300mg
Apo-gemfibrozil
PHL-gemfibrozil
Teva-gemfibrozil
Nu-gemfibrozil Cap 300mg
Penta-gemfibrozil
Scheinpharm Gemfibrozil
Mylan-gemfibrozil
Gemfibrozil-600 - Tab 600mg
Gemfibrozil-300 - Cap
Lopid
Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
